PBAC's latest decision on Enoxaparin: Recommended (2025). Considered for Prevention of thrombo-embolic disorders of venous origin in patients undergoing orthopaedic and general surgery; prophylaxis of venous thromboembolism in medical patients bedridden due to acute illness; prevention of thrombosis in extra-corporeal circulation during haemodialysis; treatment of established deep vein thrombosis; treatment of unstable angina and non-Q-wave myocardial infarction; and treatment of acute ST-segment elevation myocardial infarction.
PBAC outcome
Recommended
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
4
first 2019
Submissions
4
2019 → 2025
Eligible population
Adults with indications for enoxaparin: prevention of thrombo-embolic disorders in orthopaedic and general surgery patients; prophylaxis of venous thromboembolism in bedridden medical patients; prevention of thrombosis during haemodialysis; treatment of deep vein thrombosis, unstable angina, non-Q-wave myocardial infarction, and acute ST-elevation myocardial infarction.
Therapy area
Cardiovascular
Line of therapy
Not applicable
Evidence base
Other
Comparator
Clexane, Exarane
Economic model
Cost-minimisation
ICER note
Cost-minimisation basis; no ICER calculated as this is a biosimilar listing with expected price equivalence to existing enoxaparin brands.